CIRFF, Center of Pharmacoeconomics and Drug utilization Research, University of Naples Federico II, 80131 Naples, Italy.
Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.
Int J Environ Res Public Health. 2020 Jun 1;17(11):3926. doi: 10.3390/ijerph17113926.
A gender-specific drug utilization study was performed in the Campania region, Southern Italy. Data were based on outpatient drug prescriptions collected from administrative databases. The study population included all patients with at least one drug prescription in 2018. Prevalence was used as a measure to estimate the degree of exposure to drugs. A total of 3,899,360 patients were treated with at least one drug (54.2% females). The number of prescriptions was higher in females than males (55.6% vs. 44.4%). Females recorded higher prevalence for the majority of therapeutic groups (ATC II-anatomical therapeutic chemical), as well as for anti-inflammatory and antirheumatic products drugs (M01) (25.6% vs. 18.7%, risk ratio (RR): 0.73), beta blocking agents (C07) (14.5% vs. 11.6%, RR: 0.80), psychoanaleptics (N06) (7.1% vs. 3.7%, RR: 0.52), and antianemic preparations (B03) (2.8% vs. 6.7%, RR: 0.4). Higher prevalence was identified for males only for drugs used in diabetes (A10) (6.8% vs. 6.2%, RR: 1.1), particularly for biguanides (A10BA). Conversely, treatment duration was longer among males, explaining the higher mean cost per treated patient. This real-world study showed substantial gender differences in terms of medication use and duration of treatment and costs. These results are relevant to promoting and supporting the emerging role of precision and personalized medicine.
一项针对意大利南部坎帕尼亚地区的特定性别药物利用研究。数据基于从行政数据库中收集的门诊药物处方。研究人群包括 2018 年至少有一份药物处方的所有患者。患病率被用作衡量药物暴露程度的指标。共有 3899360 名患者至少使用了一种药物（54.2%为女性）。女性的处方数量高于男性（55.6%比 44.4%）。女性在大多数治疗组（ATC II-解剖治疗化学）以及抗炎和抗风湿产品药物（M01）（25.6%比 18.7%，风险比（RR）：0.73）、β受体阻滞剂（C07）（14.5%比 11.6%，RR：0.80）、精神兴奋药（N06）（7.1%比 3.7%，RR：0.52）和抗贫血制剂（B03）（2.8%比 6.7%，RR：0.4）方面的患病率更高。仅在男性中，用于糖尿病的药物（A10）（6.8%比 6.2%，RR：1.1）的患病率较高，特别是二甲双胍（A10BA）。相反，男性的治疗持续时间更长，这解释了每位治疗患者的平均费用较高。这项真实世界的研究表明，在药物使用、治疗持续时间和成本方面存在显著的性别差异。这些结果与促进和支持新兴的精准和个性化医学角色有关。
